ABL1 and acute lymphoblastic leukemia: The COG AALL1131 trial (NCT02883049) for patients with high-risk B-ALL was amended in 2016 to add a post-induction dasatinib non-random treatment arm, including post-induction dasatinib (NCT01406756) for those with ABL-class fusion [96].